Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502

Daniel G Stover; Roberto Salgado; Oleksander Savenkov; Karla Ballman; Erica L Mayer; Mark Jesus M Magbanua; Sherene Loi; Mark Vater; Kristyn Glover; Mark Watson; Yujia Wen; W Fraser Symmans; Charles Perou; Lisa A Carey; Ann H Partridge; Hope S Rugo

doi:10.1038/s41523-024-00683-x

Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502

NPJ Breast Cancer. 2024 Aug 21;10(1):75. doi: 10.1038/s41523-024-00683-x.

Authors

Daniel G Stover^#^{1

2}, Roberto Salgado^#^{3

4}, Oleksander Savenkov⁵, Karla Ballman⁵, Erica L Mayer⁶, Mark Jesus M Magbanua⁷, Sherene Loi⁴, Mark Vater⁸, Kristyn Glover⁸, Mark Watson⁹, Yujia Wen¹⁰, W Fraser Symmans¹¹, Charles Perou¹², Lisa A Carey¹², Ann H Partridge⁶, Hope S Rugo⁷

Affiliations

¹ Division of Medical Oncology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH, USA. daniel.stover@osumc.edu.
² Pelotonia Institute for ImmunoOncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. daniel.stover@osumc.edu.
³ GZA-ZNA Hospitals, Antwerp, Belgium.
⁴ Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁵ Alliance Statistics and Data Management Center, Weill-Cornell Medical College, New York, NY, USA.
⁶ Dana-Farber/Partners CancerCare, Boston, MA, USA.
⁷ University of California, San Francisco, San Francisco, CA, USA.
⁸ Division of Medical Oncology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
⁹ Washington University School of Medicine, St. Louis, MO, USA.
¹⁰ Alliance Protocol Operations Office, University of Chicago, Chicago, IL, USA.
¹¹ University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
¹² University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.

^# Contributed equally.

Abstract

Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502. sTILs were associated with progression-free and overall survival in chemotherapy-treated MBC when controlling for treatment arm; however, this effect did not remain significant after additional adjustment for hormone receptor status. CALGB is now part of the Alliance for Clinical Trials in Oncology. Trial Registration: ClinicalTrials.gov: NCT00785291.

Associated data

ClinicalTrials.gov/NCT00785291

Abstract

Associated data

Grants and funding